Abciximab therapy in percutaneous intervention: Economic issues in the United States

American Heart Journal

Volumn 135, Issue 4, 1998, Pages

  Goklaney, A K ^a   Murphy, J D ^a   Hillegass W B , Jr ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN; PLACEBO;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; ECONOMICS; EMERGENCY TREATMENT; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0031966339     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(98)70301-1     Document Type: Article

References (26)

1. W. Nicholson Microeconomic theory: basic principles and extensions 1992 Dryden Press Ft. Worth, Texas 181 220
2. MC Weinstein HV Fineberg AS Elstein Clinical decision analysis 1980 W.B. Saunders Philadelphia 228 265
3. WB Hillegass ED Peterson JG. Jollis What cost of therapies to reduce restenosis is justified [abstract]? Circulation 88 suppl I 1993 I145A
4. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
5. EJ Topol RM Califf HF Weisman Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 343 1994 881 886
6. DB Mark JD Talley EJ Topol Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty Circulation 94 1996 629 635
7. FV Aguirre EJ Topol JJ Ferguson Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention Circulation 91 1995 2882 2890
8. CR Narins WB Hillegass Jr CL Nelson Relation between activated clotting time during angioplasty and abrupt closure Circulation 93 1996 667 671
9. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
10. JJ Ferguson DJ Kereiakes WB Hillegass Jr Safe use of platelet GP IIb/IIIa inhibitors Am Heart J 135 1998 S77 S89
11. WB. Hillegass The economics of IIb/IIIa therapy J Invas Cardiol 8 Suppl B 1996 30B 33B
12. ST Fitzgerald A Merrill T Aversano A. Sorkin Direct and indirect cost of percutaneous transluminal coronary angioplasty Cardiology 85 1994 298 302
13. DB Mark LC Lam KL Kerry Effects of coronary angioplasty, coronary bypass surgery, and medical therapy on employment in patients with coronary artery disease: a prospective comparison study Ann Intern Med 120 1994 111 117
14. BD Hettleman RL Aplin PR Sullivan H Lemal GT O'Connor Three days of heparin pretreatment reduces major complications of coronary angioplasty in patients with unstable angina [abstract] J Am Coll Cardiol 15 1990 154A
15. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study Lancet 349 1997 1429 1435
16. Data on file. Eli Lilly and Company, Indianapolis, Ind.
17. G. Calabresi Tragic choices 1978 Norton New York
18. GA Braden RJ Applegate TM Young WW Love DC. Sane Abciximab decreases both the incidence and magnitude of creatine kinase elevation during rotational atherectomy [abstract] J Am Coll Cardiol 29 1997 499A
19. J Lefkovits JC Blankenship KM Anderson Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial J Am Coll Cardiol 28 1996 849 855
20. WB Hillegass EM Ohman MA O'Hanesian The effect of preprocedural intracoronary thrombus on patient outcome after percutaneous coronary intervention [abstract] J Am Coll Cardiol 21 1995 94A
21. DB Altmann JJ Popma MK Hong CPK-MB elevation after angioplasty of saphenous vein grafts [abstract] J Am Coll Cardiol 21 1993 232A
22. RM Challapalli MJ Eisenberg K Sigmon J. Lemberger Platelet glycoprotein IIb/IIIa monoclonal antibody (c7E3) reduces distal embolization during percutaneous intervention of saphenous vein grafts [abstract] Circulation 92 suppl I 1995 I607
23. PW Serruys P de Jaegere F Kiemeneij A comparison of balloon-expandable–stent implantation with balloon angioplasty in patients with coronary artery disease N Engl J Med 331 1994 489 495
24. DL Fischman MB Leon DS Baim A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease N Engl J Med 331 1994 496 501
25. DJ Cohen JA Breall KKL Ho Economics of elective coronary revascularization: comparison of costs and charges for conventional angioplasty, directional atherectomy, stenting, and bypass surgery J Am Coll Cardiol 22 1993 1052 1059
26. DJ Cohen JA Breall KKL Ho Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease: use of a decision-analytic model Circulation 89 1994 1859 1874